CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

Ekaphop Sirachainan,1 Sureerat Jaruhathai,1 Narumol Trachu,2 Ravat Panvichian,1 Thitiya Sirisinha,1 Touch Ativitavas,1 Vorachai Ratanatharathorn,1 Montri Chamnanphon,3 Chonlaphat Sukasem31Division of Medical Oncology, Department of Medicine, 2Research Center, Division of Pharmacogenomics and Persona...

Full description

Bibliographic Details
Main Authors:	Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-10-01
Series:	Pharmacogenomics and Personalized Medicine
Online Access:	http://www.dovepress.com/cyp2d6-polymorphisms-influence-the-efficacy-of-adjuvant-tamoxifen-in-t-a11286

Similar Items

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen
by: Chamnanphon M, et al.
Published: (2013-05-01)

Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen
by: Sensorn I, et al.
Published: (2013-08-01)

ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen
by: Sensorn I, et al.
Published: (2016-04-01)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
by: Charoenchokthavee W, et al.
Published: (2017-04-01)

Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients
by: Areepium N, et al.
Published: (2013-08-01)

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
by: Sukasem C, et al.
Published: (2013-08-01)

The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis
by: Lu J, et al.
Published: (2017-11-01)

CYP2D6 polymorphisms and their influence on risperidone treatment
by: Puangpetch A, et al.
Published: (2016-12-01)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
by: Charoenchokthavee W, et al.
Published: (2016-08-01)

The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
by: Din, J, et al.

The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
by: Din, J., et al.

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia
by: Chamnanphon M, et al.
Published: (2020-11-01)

Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population
by: Trachu N, et al.
Published: (2017-10-01)

Comparative study on the efficacy of tamoxifen and letrozole in the adjuvant hormonal therapy of postmenopausal breast cancer
by: Mei Yang
Published: (2016-05-01)

Adjuvant CMF and tamoxifen in the elderly breast cancer patients
by: Vrbavac Milenko, et al.
Published: (2002-01-01)

National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
by: Guigao Lin, et al.
Published: (2016-01-01)

Correction: National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
by: PLOS ONE Staff
Published: (2016-01-01)

Adjuvant tamoxifen therapy in older patients with operable breast cancer
by: Lakićević Jadranka, et al.
Published: (2002-01-01)

Weight change associated with adjuvant tamoxifen therapy in breast cancer
by: Chen Chun Ping, et al.
Published: (2003)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
by: Martinez-Cannon BA, et al.
Published: (2021-05-01)

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
by: Jennifer D. Brooks, et al.
Published: (2018-12-01)

The Impact of Combination Tamoxifen and CYP2D6 Inhibitory Antidepressants on The Treatment of Breast Cancer
by: Yi-Ching Wang, et al.
Published: (2013)

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
by: Jaime D. Lewis, et al.
Published: (2014-11-01)

Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.
by: Mustafa Al-Mubarak, et al.
Published: (2014-01-01)

A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study
by: Damronglerd P, et al.
Published: (2015-10-01)

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
by: Roberta Ferraldeschi, et al.
Published: (2010-04-01)

The Effects of CYP2D6*10 Polymorphisms on Tamoxifen Metabolism, Bone Mineral Density and Clinical Outcomes in Taiwanese Breast Cancer Patients and In vitro study of Tamoxifen and its Active Metabolites on Osteoclast.
by: Wu, Shang-Luen, et al.
Published: (2013)

Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
by: Tessa A. M. Mulder, et al.
Published: (2021-02-01)

Baihe Zhimu formula attenuates the efficacy of tamoxifen against breast cancer in mice through modulation of CYP450 enzymes
by: Hailong Li, et al.
Published: (2019-09-01)

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset
by: Per Damkier, et al.
Published: (2017-08-01)

Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population
by: Rattanaporn Sukprasong, et al.
Published: (2021-06-01)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
by: Clara Inkyung Lee, et al.
Published: (2020-12-01)

Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer
by: Abahssain Halima, et al.
Published: (2010-08-01)

Dietary Associations with Biomarkers of Breast Cancer Risk in Women on Adjuvant Tamoxifen Therapy
by: Strom, Meghan Brianna
Published: (2016)

CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
by: Wickramage I, et al.
Published: (2017-03-01)

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.
by: Danny W K Lum, et al.
Published: (2013-01-01)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
by: Werner Schroth, et al.
Published: (2017-08-01)

Influence of SULT1A1&ast;2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients
by: Chamnanphon M, et al.
Published: (2021-07-01)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
by: A. B. Sanchez-Spitman, et al.
Published: (2021-01-01)

Evaluation of Saline Sonohysterography Findings in Patients with Breast Cancer Receiving Tamoxifen Adjuvant Therapy
by: Maryam Rahmani, et al.
Published: (2016-12-01)